Advanced search
Publication Cover
Modern Rheumatology Volume 31, 2021 - Issue 1
Journal homepage
217
Views
7
CrossRef citations to date
0
Altmetric
Connective tissue diseases and related disorders

The assessment of tocilizumab therapy on recurrent attacks of patients with familial Mediterranean fever: A retrospective study of 15 patients

Seda ColakDepartment of Internal Medicine, Division of Rheumatology, Gulhane Medicine Faculty, University of Health Sciences, Ankara, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-5703-6739
ORCID Icon,
Emre TekgozDepartment of Internal Medicine, Division of Rheumatology, Gulhane Medicine Faculty, University of Health Sciences, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0002-0866-1503
ORCID Icon,
Muhammet CinarDepartment of Internal Medicine, Division of Rheumatology, Gulhane Medicine Faculty, University of Health Sciences, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0002-6150-3539
ORCID Icon &
Sedat YilmazDepartment of Internal Medicine, Division of Rheumatology, Gulhane Medicine Faculty, University of Health Sciences, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0002-4691-3417
ORCID Icon
Pages 223-225 | Received 02 Apr 2019, Accepted 12 Dec 2019, Published online: 10 Jan 2020

References

  • Ben-Chetrit E, Touitou I. Familial Mediterranean fever in the world. Arthritis Rheum. 2009;61(10):1447–53.
  • Onen F. Familial Mediterranean fever. Rheumatol Int. 2006;26(6):489–96.
  • Zemer D, Revach M, Pras M, Modan B, Schor S, Sohar E, et al. A controlled trial of colchicine in preventing attacks of familial Mediterranean fever. N Engl J Med. 1974;291(18):932–4.
  • Zemer D, Pras M, Sohar E, Modan M, Cabili S, Gafni J. Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever. N Engl J Med. 1986;314(16):1001–5.
  • Goldfinger S. Colchicine for familial Mediterranean fever. N Engl J Med. 1972;287(25):1302.
  • Ozen S, Kone-paut I, Gül A. Colchicine resistance and intolerance in familial Mediterranean fever: definition, causes, and alternative treatments. Semin Arthritis Rheum. 2017;47(1):115–20.
  • Koga T, Migita K, Kawakami A, Koga T, Migita K, Kawakami A. Biologic therapy in familial Mediterranean fever. Mod Rheumatol. 2016;26(5):637–41.
  • Yilmaz S, Cinar M, Simsek İ, Erdem H, Pay S. Tocilizumab in the treatment of patients with AA amyloidosis secondary to familial Mediterranean fever. Rheumatology (Oxford). 2015;54(3):564–5.
  • Hamanoue S, Suwabe T, Hoshino J, Sumida K, Hayami N, Sawa N, et al. Successful treatment with humanized anti-interleukin-6 receptor antibody (tocilizumab) in a case of AA amyloidosis complicated by familial Mediterranean fever. Mod Rheumatol. 2016;26(4):610–3.
  • Ugurlu S, Hacioglu A, Adibnia Y, Hamuryudan V, Ozdogan H. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial Mediterranean fever. Orphanet J Rare Dis. 2017;12(1):4–11.
  • Stehlik C, Reed JC. The PYRIN connection: novel players in innate immunity and inflammation. J Exp Med. 2004;200(5):551–8.
  • Bagci S, Toy B, Tuzun A, Ates Y, Aslan M, Inal A, et al. Continuity of cytokine activation in patients with familial Mediterranean fever. Clin Rheumatol. 2004;23(4):333–7.
  • Gang N, Drenth J, Langevitz P, Zemer D, Brezniak N, Pras M, et al. Activation of the cytokine network in familial Mediterranean fever. J Rheumatol. 1999;26(4):890–7.
  • Yılmaz S, Tekgöz E, Çınar M. Recurrence of proteinuria after cessation of tocilizumab in patients with AA amyloidosis secondary to FMF. Eur J Rheumatol. 2018;5(4):278–80.
  • Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959–64.
  • Umeda M, Aramaki T, Fujikawa K, Iwamoto N, Ichinose K, Terada K, et al. Tocilizumab is effective in a familial Mediterranean fever patient complicated with histologically proven recurrent fasciitis and myositis. Int J Rheum Dis. 2017;20(11):1868–71.
  • Fujikawa K, Migita K, Tsukada T, Umeda M, Nonaka F, Kawakami A, et al. Interleukin-6 targeting therapy in familial Mediterranean fever. Clin Exp Rheumatol. 2013;31(3 Suppl. 77):150–1.
  • Koga T, Sato S, Miyamoto J, Hagimori N, Kawazoe Y, Arinaga K, et al. Comparison of the efficacy and safety of tocilizumab for colchicine-resistant or colchicine-intolerant familial Mediterranean fever: study protocol for an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial. Trials. 2018;19(1):715.
  • Varan O, Kucuk H, Babaoglu H, Guven SC, Ozturk A, Haznedaroglu S, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol. 2019;29(2):363–6.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.